|
Products |
| Products |
|
Diseases |  |
News |  |
| «12...1314151617181920212223...39313932» |
- Rituxan (rituximab) / Roche
Oral Glucocorticoid Premedication Is at Least as Effective as Intravenous Glucocorticoid Premedication for Prevention of Infusion-related Reactions to Rituximab in Rheumatoid Arthritis Patients (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2491;
Oral prednisolone was at least equally effective compared to intravenous prednisolone in preventing IRRs of rituximab. Switch to oral prednisolone in the premedication of rituximab could be considered in all facilities administering rituximab to RA patients.
- obexelimab (ZB012) / Zenas BioPharma
A Population Modeling and Simulation of the Effect of Obexelimab Exposure on the QTc Interval in Healthy Volunteers and Patients with Rheumatoid Arthritis or IgG4-Related Disease (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2488;
A linear model form was adequate to predict obexelimab concentration-induced changes in QTc. Obexelimab did not produce any clinically relevant effect on electrocardiographic QTc interval in healthy volunteers, RA or IgG4-RD patients.
- Gazyva (obinutuzumab) / Roche, Biogen
Experience on the Use of Obinutuzumab off Label in Patients with Refractory Idiopathic Inflammatory Myopathy (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2441;
This is the first case series of successful and safe use of Obinutuzumab in IIM. This provides a signal to design a large-scale clinical trial with Obinutuzumab in IIM.
- Rituxan (rituximab) / Roche
A Retrospective Cohort Study Assessing Outcomes and Safety in Patients Receiving Low Dose vs High Dose Cyclophosphamide in Myositis Interstitial Lung Disease (ILD) (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2439;
P2, P2/3,
All-cause mortality numerically favoured high dose cyclophosphamide and there were significantly fewer serious infections in the HD arm. Imbalances between the groups, in terms of severity of disease, may account for these observed differences.
- Rituxan (rituximab) / Roche
Comparing the Efficacy of Conventional Immunosuppression and Rituximab in Anti-SRP Myositis: Insights from a Tertiary Care Centre Experience (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2435;
Cardiac involvement and severe muscle weakness are associated with mortality. RTX use decreases steroid requirement.
- Rituxan (rituximab) / Roche
Efficacy and Safety of a Step-down Regimen of Low Dosage of Glucocorticoids Combined with Early Administration of Synthetic or Biologic Immunosuppressants in Anti-synthetase Syndrome: A Pilot Study (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2409;
MTX, as well as other synthetic immunosuppressants, showed limited efficacy in ASS-related arthritis, while RTX emerged as a promising option. This study recommends early RTX use in case of arthritis, suggesting it as a pivotal treatment for ILD too, and raises questions regarding maintenance therapy and treatment-free remission.
- Orencia (abatacept) / BMS
The Associations Between Genetic Factors and Rheumatoid Arthritis Treatment Patterns: Data from Two Large Healthcare Systems (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2391;
These similarities were observed despite significant differences in underlying RA patient populations, including age and sex. RA patients who persisted on TNFi had non-HLA genetic differences compared to multi-bDMARD cyclers; future studies will incorporate HLA data.
- Rinvoq (upadacitinib) / AbbVie
Upadacitinib and Other JAK Inhibitors in the Treatment of Rheumatoid Arthritis - Interstitial Lung Disease. National Multicenter Study Clinical Practice. (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2344;
More studies are needed. Table.
- Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche
Exploring Two Decades of Therapeutic Challenges: A Monocentric Experience in Rheumatoid Arthritis Patients Battling Cancer (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2340;
Disease activity was the main factor for initiating bDMARD therapy post-cancer diagnosis, predominantly within the first five years, with Rituximab being the preferred option. These findings align with expert society recommendations and highlight the need for further studies to address evidence gaps in this setting.
- Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma
Association Between Body Mass Index and the Persistence of Non-TNF-Targeted Biologics in Patients with Rheumatoid Arthritis (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2331;
Patients from the KOBIO registry who had received at least one prescription for non-TNF-targeted treatments, including abatacept, tocilizumab, and JAK kinase inhibitors, were included. These findings underscore the necessity for individualized treatment approaches for RA patients with higher BMI, suggesting a differential response to non-TNF-targeted treatments based on BMI.
- rosnilimab (ANB030) / AnaptysBio
Synovial Expression Levels of PD-1, the Target of Rosnilimab, Correlate with Disease Activity and Persist Across Disease Stages and Lines of Therapy in Rheumatoid Arthritis (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2324;
P2
PD-1 associated pathways were analyzed using Gene Set Variation Analysis (GSVA) on two gene sets: a nivolumab-induced gene set (Choueiri et al 2016), and a rosnilimab-induced gene set generated using RNA-seq data from purified T cells co-cultured with monocyte-derived DCs and rosnilimab. Synovial PD-1 and CXCL13 expression levels correlate with clinical markers of disease and persist across na
- Orencia (abatacept) / BMS
CXC Chemokine Ligand 13 and Rheumatoid Factor as Pharmacodynamic Biomarkers for Abatacept Treatment in Patients with Rheumatoid Arthritis (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2312;
In patients with RA, ongoing immune complex-driven immune activation, as defined by heightened levels of anti-CCP, IgM RF, NE-DNA complexes, calprotectin, CXCL13, and IL-21, predicted the treatment response to abatacept. Further, IgM RF and CXCL13 levels were superior to anti-CCP in assessing and monitoring the response to abatacept.
- Rituxan (rituximab) / Roche
Low CD47 Expression on B Cells, Induces High B Cell Phagocytosis by Macrophages and Is a Predictive Biomarker of Anti-rituximab Antibodies and Lower Response in Rheumatoid Arthritis (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2294;
RTX mediated phagocytosis of B-cells by macrophages is increased when CD47 expression is low on target B cells. But rather than leading to an increased response by increasing B-cell depletion, it is associated with higher levels of ADAb yielding lower response to RTX in RA patients.
- Benlysta (belimumab) / GSK, Rituxan (rituximab) / Roche
Lupus Lymphocyte Activation Score of Pathologic T and B Cell Phenotypes Increased in Patients at Risk of Systemic Lupus Erythematosus (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2283;
Using flow cytometry with limited markers, we defined a LLAS score capturing key lymphocyte subsets implicated in SLE immune dysregulation. LLAS was highly expanded in SLE patients and in patients developing SLE (vs. ANA+ only patients), suggesting a role for LLAS as an early SLE biomarker.
- Benlysta (belimumab) / GSK, Saphnelo (anifrolumab-fnia) / AstraZeneca, Rituxan (rituximab) / Roche
Chart Audit of over 1,000 SLE Patients Reveals Biologic Treatment Choice Driven by Disease Manifestations (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2253;
These findings highlight the individualized treatment strategies being employed in managing SLE, particularly in addressing the diverse manifestations of the disease in order to optimize patient outcomes. Further studies are warranted to establish the long-term efficacy and safety of anifrolumab in the treatment of CLE patients.
- Benlysta (belimumab) / GSK, Rituxan (rituximab) / Roche
Differential Impact of B-cell Targeted Monotherapy and Combination Regimen on the Peripheral Blood Transcriptome of Adults with Active Sj (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2247;
P2
B cell targeted treatments alone and in combination impact the peripheral blood transcriptome in adults with SD. The differential effect of treatment on responders vs. non-responders, highlights the role of B cells in SD disease pathogenesis.
- Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche
Sj (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2238;
Only 9.4% of the patients met the criteria for PPF, and there were no acute exacerbations or deaths. However, larger cohorts and longer follow-ups are needed to confirm these findings.
- iscalimab (CFZ533) / Novartis, remibrutinib (LOU064) / Novartis
A Post-hoc Analysis of Two Phase 2 Randomized Controlled Trials in Patients with Active Sjogren's Disease Exploring the Novel Composite Endpoint Sj (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2232;
P2
However, larger cohorts and longer follow-ups are needed to confirm these findings. Background/Purpose: Two randomized controlled phase 2 trials in patients with active Sjogren's disease (SjD) were recently completed, the LOUiSSe trial assessing the Bruton Tyrosine kinase inhibitor remibrutinib (LOU064; NCT04035668; D
- Gazyva (obinutuzumab) / Roche, Biogen
Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2227;
P2, P3
Beneficial effects of obinutuzumab were also demonstrated regardless of baseline levels of proteinuria. Obinutuzumab is currently undergoing further evaluation in patients with active proliferative LN in the global, registrational, Phase III REGENCY trial (NCT04221477).
- Benlysta (belimumab) / GSK, Saphnelo (anifrolumab-fnia) / AstraZeneca, Rituxan (rituximab) / Roche
Early Introduction of Biologic Agents in Systemic Lupus Erythematosus Reduces Relapse and Glucocorticoid Maintenance Dose: A Cohort Study from the PLEAJURE J Registry (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2213;
Early introduction of biologic agents in SLE not only suppresses disease relapse but also enables a reduction in the maintenance PSL dose. The early introduction of biologic agents may positively impact long-term outcomes over a period of 3 years.
- BCMA-CD19 cCAR T cells / iCell Gene Therap
BCMA-CD19 Compound CAR-T (cCAR) Safely Provides a Complete Humoral Reset Eliminating All Autoantibodies Resulting in Long-term Medication-Free Complete Remission Among Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Patients (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2201;
Will update dataset at ACR. Further research needed.
- Can Immunosuppression or Vasodilation Prevent the Onset of Interstitial Lung Disease in Systemic Sclerosis? An Association Analysis from the EUSTAR Database (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2168;
Further research needed. Exposure included the use of any IMS (mycophenolate mofetil, cyclophosphamide, azathioprine, methotrexate, prednisone over 10 mg/day
- MG 519 / BMS, Rituxan (rituximab) / Roche
Outcomes of Intermittent Intravenous Steroid Use During Infusion Therapy in Systemic Sclerosis (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2133;
With increasing use of biologic medications such as rituximab (RTX), we studied whether intermittent high dose IV corticosteroid premedication is associated with development of SRC in SSc patients. We performed a retrospective observational study of EMR data from 155 SSc patients seen long-term in Rheumatology Clinic at University of New Mexico Hospital between January 2009 and December 2023...In the infusion group, one patient developed SRC prior to first infusion, but across a total of 827 infusions with a mean of 21
- Rituxan (rituximab) / Roche
Diffuse Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Revisited (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2120;
Over the 11 year period comprising the recent cohort, rituximab has emerged as the most frequently used remission induction agent for patients with DAH and AAV. This was not accompanied by any difference in outcomes.
- Rituxan (rituximab) / Roche
Factors Associated with Relapses and Performance of the French Vasculitis Study Group Relapse Score in a Cohort of Mexican Patients with ANCA-Associated Vasculitis (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2107;
Nearly half of the patients had a FRS of 3 points at diagnosis. Risk factors associated with relapse included the individual components of the FRS, and the 5-year relapse risk was 40% for a FRS of 1, %, 41% for a FRS of 2, and 66% for a FRS of 3.
- Rituxan (rituximab) / Roche
Management of ANCA Vasculitis-Associated Orbital Inflammatory Disease: A Systematic Literature Review (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2100;
Pooled estimates showed that over three quarters of individuals achieved clinical remission with RTX at 6 months, and qualitatively, high rates of remission were reported for RTX + conventional IS. Our results emphasize the necessity of larger, prospective studies examining treatments for AAV-associated OID.
- Nucala (mepolizumab) / GSK, Rituxan (rituximab) / Roche
Assessment of the Quality of Life in a Single-center Cohort of Patients with ANCA-Associated Vasculitis on Targeted Therapy: Characterization of Global, Disease and Organ-specific Parameters Using Patient Reported Outcomes (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2092;
Our results emphasize the necessity of larger, prospective studies examining treatments for AAV-associated OID. All patients had been on a targeted therapy (Rituximab 500 mg/6 months or on-demand for Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA), Mepolizumab 300 mg/4 weeks for Eosinophilic Granulomatosis with Polyangiitis (EGPA)) for at least 6 months...37.8% of patients were taking prednisone (mean daily dose of 3.77
- Benlysta (belimumab) / GSK, Saphnelo (anifrolumab-fnia) / AstraZeneca
Comparative Harms in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab or Belimumab: A Multicenter Cohort Study Using the TriNetX Research Network (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2016;
The censored dates were 90 days after the last dose of biologics, the date of switching to the other biologic, the date of death, or the last date of the dataset (i.e., December 5, 2023), whichever occurred first.After adjusting for potential confounders, including age, sex, race, history of herpes zoster vaccination, comorbidities including diabetes, hypertension, malignancies, diseases of arteries, arterioles and capillaries, and spondyloarthritis, and use of medications including rituximab, leflunomide, methotrexate, hydroxychloroquine, mycophenolic acid/mycophenolate mofetil, calcineurin inhibitors, azathioprine, corticosteroid and non-steroidal anti-inflammatory drugs within one year before the index date, the relative risks of various adverse events in anifrolumab-treated SLE patients compared with belimumab-treated SLE patients were estimated using multivariable Cox regression analyses, presented as adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs). The mean
- imvotamab (IGM-2323) / IGM Biosciences
Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, Effectively Depletes Low-Expressing CD20+ B Cells in Preclinical Models of Autoimmune Disease (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2000;
P1
Results using a low expressing CD20+ cell line further substantiate this finding, supporting the potential for improved killing of key pathogenic B cell subsets by imvotamab over rituximab. Imvotamab is currently being evaluated in phase 1b clinical trials with severe SLE (NCT# NCT06041568) and moderate to severe RA (NCT# NCT06087406).
- Cimzia (certolizumab pegol) / Astellas, UCB
Fragment Crystallizable (Fc)-Free Certolizumab Pegol Is Not Bound by Rheumatoid Factors, While Fc Containing Biological DMARDsAre, Driving ImmuneComplex Formation and Cellular Clearance (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1956;
P4
RF binding to ADA drove protein complex formation, which stimulated macrophage mediated protein complex clearance. These findings provide insights into why CZP efficacy is independent of patient RF level, while patients with RA and high RF levels, exhibit reduced serum drug concentrations and treatment outcomes when treated with Fc-containing bDMARDs, compared to those patients with lower RF levels.
- STK-009/SYNCAR-001 / Synthekine, Rituxan (rituximab) / Roche
SYNCAR: An Engineered IL-2/IL-2R-system That Selectively Enhances CD19 CAR T Cells to Deplete B Cells and Provide Therapeutic Benefit in SLE and RA Mouse Models Without Lymphodepletion (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1923;
P1
These findings support clinical exploration of SYNCAR-001 + STK-009 in AI diseases like SLE and RA to achieve CD19 CAR T expansion and significant B cell aplasia without genotoxic, lymphodepleting agents. SYNCAR-001 + STK-009 is in Phase I trials for heme malignancies (NCT05665062), with LN and SLE patient enrollment expected later this year.
- Tai'ai (telitacicept) / Rongchang Pharma, Rituxan (rituximab) / Roche
The Efficacy and Safety of Telitacicept Following Rituximab Immunotherapy on Antiphospholipid Syndrome, a Prospective 24- Week Study (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1843;
In this 24w prospective observational study, RTX followed by TA therapy was a promising strategy for refractory/severe APS. This immunotherapy strategy effectively reduced the incidence of new-onset APS-related events and lowered aPL values without increasing new infections using TA.
- Ambient Air Pollution and Initiation of bDMARDs in Newly Diagnosed Rheumatoid Arthritis: A Nested Case-Control Study of NIH All of Us Cohort (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1726;
The associations were consistent across various exposure periods. Further studies on larger cohorts are needed to confirm the results.
- Orencia (abatacept) / BMS, Rituxan (rituximab) / Roche
Real-World Treatment Patterns of Clinical Practice Guideline Therapies in Rheumatoid Arthritis-Associated Interstitial Lung Disease (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1687;
These findings help contextualize the guideline, highlight the heterogeneity of RA-ILD, and suggest that treatment decisions in RA-ILD are guided by several patient factors, including those beyond ILD severity. Further research is needed to evaluate treatment patterns in specific RA-ILD populations, including individuals with a progressive course.
- Orencia (abatacept) / BMS
Immunogenicity of the Recombinant Zoster Vaccine in People with Rheumatoid Arthritis Using Abatacept (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1666;
P2
Antibody responses to RZV were lower in magnitude and frequency than those previously described. These results raise the possibility that RZV may not confer adequate protection against HZ in people with RA taking abatacept.
- Rituxan (rituximab) / Roche
Anti-Spike Antibodies in SARS-CoV-2-Vaccinated SLE Patients (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1631;
We show that treatment with either rituximab or mycophenolate, but not prednisone, significantly blunts the humoral immunogenicity of SARS-CoV2 mRNA vaccines. Our results also suggest that, while the anti-spike antibodies produced by SLE patients have similar avidity, they have decreased ability to neutralize virus in comparison to the antibodies produced by healthy controls.
- Use of Outpatient Antiviral Therapy and Severe Outcomes from SARS-CoV-2 Omicron Infection in Patients with Immune Mediated Diseases on B Cell Depleting Agents (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1629;
In this observational cohort study of IMIDs patients with indications for anti-CD20 therapy, treatment with nirmatrelvir/ritonavir was associated with lower rates of hospitalization and death from COVID-19. Despite improved outcomes of SARS-CoV-2 infection during Omicron compared to prior epochs, patients receiving BCDT remain high risk for poor outcomes and should continue to be offered early outpatient treatment with nirmatrelvir/ritonavir.
- Orencia (abatacept) / BMS, Humira (adalimumab) / AbbVie, Rituxan (rituximab) / Roche
Humoral Response to SARS-CoV-2 Vaccination and Breakthrough COVID-19 Disease in Patients with Immune-mediated Inflammatory Diseases Receiving Biological Treatment (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1627;
Lower Ab levels were associated with rituximab-therapy and older age. Disease activity, csDMARD or CS use had no effect.
- Benlysta (belimumab) / GSK, Rituxan (rituximab) / Roche
Adjunctive Belimumab Exerts Favorable Ferritin Recovery and Survival for Post-COVID Interstitial Lung Disease in Patients with Immune Mediated Inflammatory Diseases Treated with Rituximab: A Case Series (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1625;
Adjunctive belimumab for refractory post-COVID ILD exerts favorable ferritin recovery and survival. Combinational extended antiviral regimen potentially reduces mortality in post-COVID ILD.
- Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
Recombinant Herpes Zoster Vaccine in a Large Cohort of Autoimmune Rheumatic Diseases Patients: An Interim Analysis of a Prospective Randomized Phase 4 Study (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1617;
P4
Combinational extended antiviral regimen potentially reduces mortality in post-COVID ILD. The new recombinant vaccine against HZ (RZV, Shingrix
- Recommendations for the Perioperative Use of DMARDs in Rheumatic Diseases: A Scoping Review (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1613;
There is a lack of high quality evidence to support recommendations for non-elective, non-orthopaedic surgery cases. Variations in recommendations were more common for csDMARDs compared to b/tsDMARDs, potentially leading to more practice variation in csDMARD use in the perioperative period.
- Rituxan (rituximab) / Roche
Prospective Study of Severe Infectious Events and Immune Reconstitution After Rituximab in Autoimmune Diseases (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1608;
P=N/A
B cell depletion and decreased neutrophils count appeared to be directly linked to RTX administration and underlying disease. IgG levels trajectories were influenced by GC and underlying disease.
- Annual Cost of Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1576;
Moreover, the evaluation of trends revealed a significant increase in the annual treatment costs of TNFi bDMARDs. The FDA authorization of biosimilars significantly reduced the annual cost of bDMARDs used in RA treatment.
- Kalydeco (ivacaftor) / Vertex, Rituxan (rituximab) / Roche
Joint Involvement in Cystic Fibrosis: Description of Clinical Phenotypes (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1550;
The incidence of RA in our CF population was high (1/3 of patients), indicating a close lung-joint connection in this rheumatism. Treatment with corticosteroids, Methotrexate, and/or biologics did not appear to increase infectious risk.
- Rituxan (rituximab) / Roche
Hypersensitivity Pneumonitis with Autoimmune Features: A New Entity? (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1549;
HP and various CTD share a dysregulation of T cells, which could explain the higher incidence of autoimmune disease in patients with HP. It remains to be determined whether HPAF is a distinct clinical phenotype of HP.
- Rituxan (rituximab) / Roche
Effectiveness of Rituximab in IgG4 Related Disease (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1548;
RTX seems to be an effective and relatively safe therapy in IgG4-RD. Maintenance treatment with RTX seems to be associated with a low rate of relapse.
- nintedanib / Generic mfg.
Real-World Tolerability of Nintedanib in Connective Tissue Disease-Associated Interstitial Lung Disease (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1538;
Gastrointestinal side effects were common and were often the reason for medication discontinuation. Due to side effects and medication cost, a minority of patients were able to tolerate the standard dose of nintedanib long-term.
- Benlysta (belimumab) / GSK, Rituxan (rituximab) / Roche
Severe Infection in COVID-19 Vaccinated Patients with Systemic Autoimmune Rheumatic Diseases on B Cell Targeted Therapies: Association with Neutrophil-lymphocyte Ratio (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1533;
Due to side effects and medication cost, a minority of patients were able to tolerate the standard dose of nintedanib long-term. Some laboratory parameters play a crucial role in assessing infection risk.Objective: To evaluate risk factors associated with severe infection during B-lymphocyte targeted therapy in vaccinated patients and the relationship between neutrophil
- Rituxan (rituximab) / Roche
Progressive Fibrosing Intersticial Lung Disease of Autoimmune Origin and Antifibrotic Medication: NEREA Registry (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1520;
Most patients at antifibrotic treatment were on concomitant DMARDs. Greater persistence of antifibrotics is observed in patients with bDMARDs, NSIP-type radiological pattern, and systemic autoimmune.
- CABA-201 / Cabaletta Bio
Correlative Studies of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1513;
P1/2
These emerging data detail the pharmacokinetics and pharmacodynamics of CABA-201 in IIM and SLE. Evaluation of the selected CABA-201 dose continues in the ongoing RESET-Myositis and RESET-SLE trials.